We are Sorry, This Page doesn't Exist

AbbVie (ABBV) inks deal with Tizona Therapeutics, to develop and commercialize CD39-targeted therapeutics, including TTX-030, which is a first-in-class antibod.....»»

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has read more.....»»

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ: BLU) read more.....»»

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, develop.....»»

Shares of Forty Seven Inc. shot up 61% in premarket trading Monday, after the immuno-oncology company agreed to be acquired by Gilead Sciences Inc. in a cash deal valued at $4.9 bill.....»»

Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

TORONTO and HOUSTON, Nov. 5, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQB:MDNAF), a clinical stage immuno-oncology company, today reported financial results for the three and si.....»»

The company's first full-time CEO was formerly the COO at Spark Therapeutics......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Lilly (LLY) inks a deal with the privately held Centrexion Therapeutics to add the latter's early-stage pain candidate, CNTX-0290, to its portf.....»»

Eli Lilly & Co. will buy the immuno-oncology biotech ARMO Biosciences Inc. for about $1.6 billion in an all-cash deal, the company announced early Thursday. ARMO Biosciences shares surged 77.6% .....»»

The deal, which comes just four months after Armo went public, would give Lilly access to the smaller drug developer's lead immuno-oncology candidate, pegilodecakin......»»

Shares of Netherlands-based biotech argenx SE – ADR (NASDAQ: ARGX) were trading up Wednesday following an announ read more.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Clinical-stage immuno-oncology company Allogene Therapeutics has filed with the SEC in regards to its initial public offering......»»

United Therapeutics Inks Deal With Samumed. What Investors Need To Consider.....»»

Cara Therapeutics Inks Distribution Deal, Stock Will Push Higher.....»»

Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molec.....»»